Chromadex (NASDAQ:CDXC) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.
Insider and Institutional Ownership
17.3% of Chromadex shares are held by institutional investors. Comparatively, 16.0% of Mannatech shares are held by institutional investors. 10.3% of Chromadex shares are held by insiders. Comparatively, 24.7% of Mannatech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Chromadex and Mannatech, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Chromadex currently has a consensus price target of $6.00, indicating a potential upside of 73.91%. Given Chromadex’s higher probable upside, research analysts clearly believe Chromadex is more favorable than Mannatech.
This table compares Chromadex and Mannatech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Chromadex has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500.
Valuation & Earnings
This table compares Chromadex and Mannatech’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Chromadex||$21.20 million||8.97||-$11.37 million||($0.35)||-9.86|
|Mannatech||$176.70 million||0.27||-$1.78 million||N/A||N/A|
Mannatech has higher revenue and earnings than Chromadex.
Mannatech pays an annual dividend of $2.00 per share and has a dividend yield of 10.1%. Chromadex does not pay a dividend. Mannatech has increased its dividend for 2 consecutive years.
Mannatech beats Chromadex on 9 of the 13 factors compared between the two stocks.
ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation has a strategic partnership for healthy aging research with the Jiangxi Provincial Government, the People's Republic of China. ChromaDex Corporation is based in Irvine, California.
Mannatech, Incorporated provides wellness solutions. The company develops, markets, and sells nutritional supplements, topical, skin care and anti-aging products, and weight-management products. It markets its products through network marketing channels in the Americas, Europe/the Middle East/Africa, and the Asia/Pacific. The company was founded in 1993 and is headquartered in Coppell, Texas.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.